X-Message-Number: 26745
Date: Mon, 1 Aug 2005 14:25:02 +0200
From: Eugen Leitl <>
Subject: can somebody verify this?



http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050718005106&newsLang=en

 July 18, 2005 07:00 AM US Eastern Timezone


Human BioSystems Successfully Transplants Kidneys Stored at Suspended Animation 
Temperatures


PALO ALTO, Calif.--(BUSINESS WIRE)--July 18, 2005--Human Biosystems (OTCBB:HBSC)
announces today that it was successful in transplanting animal kidneys 
preserved in the Company's proprietary "HBS Preservation Solution" after being 
stored in liquid Nitrogen at -196 degrees Centigrade.


Dr. Luis Toledo, Chief Medical Officer for HBS states, "We believe that this is 
the first time that an organ stored at such a low temperature was then thawed 
and transplanted back into the animals while still maintaining some of its 
functional response as evidenced by the presence of urine. In this series of 
experiments, three rat kidneys, containing the 'HBS Preservation Solution', were
stored at -196 degrees Centigrade for 3, 5 and 7 days respectively, then 
returned to room temperature prior to transplantation back into the animal. All 
three kidneys produced urine after transplantation, the most important 
indication of organ viability. All kidneys tested in these experiments had a 
Reperfusion Index of 14 out of a possible15 (the RPI is one indicator of an 
organs viability), which is excellent."


Dr. Toledo added, "This extremely low temperature causes all metabolic activity 
to virtually cease. An organ stored at this temperature remains in a state of 
suspended animation known as vitrification. In order to achieve the successful 
vitrification of an organ, many obstacles must be overcome; including the 
effects that freezing has on the organ. The damage caused by the crystallization
and expansion of water in an unprotected organ is catastrophic, causing cells 
to be completely destroyed."


"HBS Preservation Solution limited expansion to about one tenth to that of 
normal water expansion and caused the water to freeze in a different way, thus 
avoiding the normal organ damage resulting from water freezing," stated Dr. 
Fernando Lopez, Senior Research Scientist for HBS.


"This latest milestone represents the potential for our technology to become an 
enabling technology for not only organ preservation uses, but for applications 
we never imagined possible," states Harry Masuda, CEO of HBS.


HBS is headquartered in Palo Alto, California with research facilities in 
Michigan.


Certain statements contained herein are ``forward-looking'' statements (as such 
term is defined in the Private Securities Litigation Reform Act of 1995). 
Because such statements include risks and uncertainties, actual results may 
differ materially from those expressed or implied by such forward-looking 
statements. Factors that could cause results to differ materially from those 
expressed or implied by such forward-looking statements include, but are not 
limited to, results from ongoing research and development as well as clinical 
studies, failure to obtain regulatory approval for the Company's products, if 
required, failure to develop a product based on the Company's technology, 
failure of any such products to compete effectively with existing products, the 
ability of the Company to fund marketing and sales efforts that may be required 
to effectively sell its products .and other factors discussed in filings made by
the Company with the Securities and Exchange Commission.

Human BioSystems (OTC Bulletin Board:HBSC)

-- 
Eugen* Leitl <a href="http://leitl.org">leitl</a>
______________________________________________________________
ICBM: 48.07100, 11.36820            http://www.leitl.org
8B29F6BE: 099D 78BA 2FD3 B014 B08A  7779 75B0 2443 8B29 F6BE

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=26745